Advanced stage pancreatic cancer: novel therapeutic options

References

• American Cancer Society. Cancer Facts & Figures 2013. American Cancer Society; Atlanta, GA: 2013
   Google Scholar
• Saif MW. Advancements in the management of pancreatic cancer: 2013. JOP 2013;14(2):112-18
   PubMedGoogle Scholar
• Rubin J, Gallagher JG, Schroeder G, et al. Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma. Cancer 1996;78:1888-91
   PubMed Web of Science ®Google Scholar
• Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 1985;253:2061-7
   PubMed Web of Science ®Google Scholar
• Carmichael J, Fink U, Russell RC, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996;73:101-5
   PubMed Web of Science ®Google Scholar
• Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2,2’-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12:29-34
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13
   PubMed Web of Science ®Google Scholar
• Oettle H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer. JAMA 2007;297:267-77
   PubMed Web of Science ®Google Scholar
• Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002;20:3270-5
   PubMed Web of Science ®Google Scholar
• Reiss H, Helm A, Niedergethmann M, et al. A randomized, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005. ASCO Annual Meeting Proceedings; 23(Suppl); LBA4009
   Google Scholar
• Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007;25:2212-17
   PubMed Web of Science ®Google Scholar
• Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22:3776-83
   PubMed Web of Science ®Google Scholar
• Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:3946-52
   PubMed Web of Science ®Google Scholar
• Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23:3509-16
   PubMed Web of Science ®Google Scholar
• Cheverton P, Friess H, Andras C, et al. Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naïve patients with advanced pancreatic cancer (APC). J Clin Oncol 2004. ASCO Annual Meeting Proceedings (Post-Meeting Edition); 22(Suppl); 4005
   Google Scholar
• Oettle H, Richards D, Ramanathan RK, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005;16(10):1639-45
   PubMed Web of Science ®Google Scholar
• Moore MJ, Hamm J, Dancey J, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:3296-302
   PubMed Web of Science ®Google Scholar
• Lersch C, van Cutsem E, Amado R, et al. Randomized phase II study of SCH 66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas. Proc Am Soc Clin Oncol 2001;20: Abstract 608
   Google Scholar
• Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010;28(22):3617-22
   PubMed Web of Science ®Google Scholar
• Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010;28(22):3605-10
   PubMed Web of Science ®Google Scholar
• Kindler HL, Ioka T, Richel DJ, et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 2011;12(3):256-62
   PubMed Web of Science ®Google Scholar
• Gonçalves A, Gilabert M, François E, et al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol 2012;23(11):2799-805
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1619-703
   Web of Science ®Google Scholar
• Saif MW. Is there a standard of care for the management of advanced pancreatic cancer? Highlights from the Gastrointestinal Cancers Symposium; Orlando, FL, USA. January 25-27, 2008. JOP 2008. 9(2):91-8
   Google Scholar
• Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011;29(34):4548-54
   PubMed Web of Science ®Google Scholar
• Fine RL, Fogelman DR, Schreibman SM, et al. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol 2008;61:167-75
   PubMed Web of Science ®Google Scholar
• Fine R, Moorer G, Sherman W, et al. Phase II trial of GTX chemotherapy in metastatic pancreatic cancer. J Clin Oncol 2009;27(15 Suppl): Abstract 4623
   Google Scholar
• Kang SP, Saif MW. Three-drug combination regimen in pancreatic cancer treatment: are we there yet? JOP 2011;12(2):78-82
   PubMedGoogle Scholar
• Kindler HL, Bylow KA, Hochster HS, et al. A randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis. J Clin Oncol 2006;24(18 Suppl): Abstract 4040
   Web of Science ®Google Scholar
• Kullmann F, Hollerbach S, Dollinger M, et al. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in 1st line metastatic pancreatic cancer. First results from a multicenter phase II study [abstract 128]. Proc ASCO Gastrointestinal Cancers Symposium; 2007
   Google Scholar
• Correale P, Montagnani F, Miano S, et al. Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer. J Chemother 2008;20:119-25
   PubMed Web of Science ®Google Scholar
• Garnier C, Rebischung C, Chirpaz E, et al. Phase II study of a combination with leucovorin (LV), 5-FU bolus and infusion (FU), gemcitabine and oxaliplatin (FOLFU GEMOX regimen) in locally advanced (LA) and metastatic (M) pancreatic carcinoma (APC). Proc Am Soc Clin Oncol 2001;20: Abstract 620
   Google Scholar
• Oh D, Lee K, Lee K, et al. A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. J Clin Oncol 2009;27(15 Suppl): Abstract 4607
   Google Scholar
• Kozuch P, Areneo M, Homel P, et al. Biweekly sequential gemcitabine, 5-FU (5-fluorouracil), LV (leucovorin), and cisplatin (GFP): a highly active novel combination for metastatic adenocarcinoma of the exocrine pancreas (MPAC). Proc Am Soc Clin Oncol 2001;20: Abstract 617
   Google Scholar
• Kozuch P, Grossbard ML, Barzdins A, et al. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 2001;6:488-95
   PubMed Web of Science ®Google Scholar
• Reni M, Passoni P, Panucci MG, et al. Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. J Clin Oncol 2001;19:2679-86
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009;27(13):2231-7
   PubMed Web of Science ®Google Scholar
• Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011;47:1676-81
   PubMed Web of Science ®Google Scholar
• Xiong HQ, Varadhachary GR, Blais JC, et al. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008;113:2046-52
   PubMed Web of Science ®Google Scholar
• Yoo C, Hwang JY, Kim JE, et al. A randomised phase II study of modified FOLFIRI.3 vs. modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 2009;101:1658-63
   PubMed Web of Science ®Google Scholar
• Ychou M, Desseigne F, Guimbaud R, et al. Randomized phase II trial comparing folfirinox (5FU/leucovorin (LV), irinotecan (I) and oxaliplatin (O)) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial. J Clin Oncol 2007;25(18 Suppl): Abstract 4516
   Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364(19):1817-25
   PubMed Web of Science ®Google Scholar
• Saif MW, Chabot J. Chemotherapy: metastatic pancreatic cancer – is FOLFIRINOX the new standard? Nat Rev Clin Oncol 2011;8(8):452-3
   PubMed Web of Science ®Google Scholar
• Burtness BA, Powell ME, Berlin JD, et al. Phase II ECOG trial of irinotecan/docetaxel with or without cetuximab in metastatic pancreatic cancer: Updated survival and CA19-9 results. J Clin Oncol 2008;26(15 Suppl): Abstract 4642
   Google Scholar
• Lubner SJ, Schelman WR, Mulkerin D, et al. Phase II study of oxaliplatin, high-dose capecitabine, and sorafenib in patients with advanced pancreatic cancer. J Clin Oncol 2010;28(15 Suppl): Abstract 4143
   Google Scholar
• Reni M, Panucci MG, Passoni P, et al. Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial. Cancer Invest 2004;22:688-96
   PubMed Web of Science ®Google Scholar
• Mallinson CN, Rake MO, Cocking JB, et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. BMJ 1980;281:1589-91
   PubMed Web of Science ®Google Scholar
• Palmer KR, Kerr M, Knowles G, et al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994;81:882-5
   PubMed Web of Science ®Google Scholar
• Starling N, Watkins D, Cunningham D, et al. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer. J Clin Oncol 2009;27(33):5499-505
   PubMed Web of Science ®Google Scholar
• Saif MW. Research in pancreatic cancer: an update after ASCO 2012. JOP 2012;13(4):330-1
   PubMedGoogle Scholar
• Remmers N, Bailey JM, Mohr AM, et al. Molecular pathology of early pancreatic cancer. Cancer Biomark 2011;9:421-40
   Web of Science ®Google Scholar
• Philip PA, Goldman BH, Ramanathan RK, et al. Phase I randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib as first-line treatment in patients with metastatic pancreatic cancer (SWOG-0727). J Clin Oncol 2012;30(Suppl 4): Abstract 198
   Google Scholar
• Amgen. Available from: www.amgen.com/media/media_pr_detail jsp?releaseID=1723925
   Google Scholar
• Michl P, Downward J. Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers. Z Gastroenterol 2005;43:1133-9
   Google Scholar
• Yamamoto S, Tomita Y, Hoshida Y, et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 2004;10:2846-50
   PubMed Web of Science ®Google Scholar
• Onconova. Available from: http://investor.onconova.com/releasedetail.cfm?ReleaseID=814465
   Google Scholar
• Strimpakos AS, Karapanagiotou EM, Saif MW, Syrigos KN. The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev 2009;35(2):148-59
   PubMed Web of Science ®Google Scholar
• Wolpin BM, Hezel AF, Abrams T, et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 2009;27:193-8
   PubMed Web of Science ®Google Scholar
• Pollak M. Metformin and pancreatic cancer: a clue requiring investigation. Clin Cancer Res 2012;18:2723-5
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(adp-ribose) polymerase in tumors from brca mutation carriers. N Engl J Med 2009;361:123-34
   PubMed Web of Science ®Google Scholar
• Leung K, Saif MW. BRCA-associated pancreatic cancer: the evolving management. JOP 2013;14(2):149-51
   PubMedGoogle Scholar
• Javle M, Curtin NJ. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther Adv Med Oncol 2011;3(6):257-67
   PubMedGoogle Scholar
• Dimou A, Syrigos K, Saif MW. Rationale for inhibition of the hedgehog pathway paracrine loop in pancreatic adenocarcinoma. JOP 2011;12(1):1-5
   PubMedGoogle Scholar
• Shafaee Z, Schmidt H, Du W, et al. Cyclopamine increases the cytotoxic effects of paclitaxel and radiation but not cisplatin and gemcitabine in Hedgehog expressing pancreatic cancer cells. Cancer Chemother Pharmacol 2006;58:765-70
   PubMed Web of Science ®Google Scholar
• Feldmann G, Dhara S, Fendrich V, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 2007;67:2187-96
   PubMed Web of Science ®Google Scholar
• Feldmann G, Fendrich V, McGovern K, et al. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther 2008;7:2725-35
   PubMed Web of Science ®Google Scholar
• Vismodegib and gemcitabine hydrochloride in treating patients with advanced pancreatic cancer. Available from: http://clinicaltrials.gov/show/NCT01195415
   Google Scholar
• Quintás-Cardama A, Verstovsek S. Molecular pathways: jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res 2013;19(8):1933-40
   PubMed Web of Science ®Google Scholar
• FirstWordPharma. Available from: www.firstwordpharma.com/node/1133046?tsid=17#axzz2sayzAB5H
   Google Scholar
• Merika EE, Syrigos KN, Saif MW. Desmoplasia in pancreatic cancer. Can we fight it? Gastroenterol Res Pract 2012;2012:781765
   PubMed Web of Science ®Google Scholar
• Hilbig A, Oettle H. Transforming growth factor beta in pancreatic cancer. Curr Pharm Biotechnol 2011;12:2158-64
   PubMed Web of Science ®Google Scholar
• Oettle H, Hilbig A, Seufferlein T, et al. Phase I/II study with trabedersen (AP 12009) monotherapy for the treatment of patients with advanced pancreatic cancer, malignant melanoma, and colorectal carcinoma. J Clin Oncol 2011;29: Abstract 2513
   Web of Science ®Google Scholar
• Hingorani SR, Harris WP, Thaddeus BJ, et al. A phase Ib study of gemcitabine plus PEGPH20 (pegylated recombinant human hyaluronidase) in patients with stage IV previously untreated pancreatic cancer. J Clin Oncol 2013(Suppl): Abstract 4010
   Google Scholar
• Saif MW, Podoltsev NA, Rubin MS, et al. Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer. Cancer Invest 2010;28(2):186-94
   PubMed Web of Science ®Google Scholar
• The New York Times. Available from: www.nytimes.com/2013/01/23/business/pancreatic-cancer-drug-found-to-extend-life.html [Last assessed 26 October 2013]
   Google Scholar
• Saif MW. Erlotinib: the first biologic in the management of pancreatic cancer. Expert Opin Pharmacother 2008;9(9):1595-607
   PubMed Web of Science ®Google Scholar
• Huang ZQ, Buchsbaum DJ, Raisch KP, et al. Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody. J Surg Res 2003;111:274-83
   PubMed Web of Science ®Google Scholar
• Loges S, Schmidt T, Carmeliet P. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer 2010;1(1):12-25
   PubMedGoogle Scholar
• Dodson LF, Hawkins WG, Goedegebuure P. Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy 2011;3:517-37
   PubMed Web of Science ®Google Scholar
• Saif M, Lee Y, Kim R. Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer. Ther Adv Med Oncol 2012;4(6):341-6
   PubMed Web of Science ®Google Scholar